Repligen

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell Repligen and other ETFs, options, and stocks.

About RGEN

Repligen Corp. is a global life sciences company, which engages in providing bioprocessing technologies and solutions used in the process of manufacturing biological drugs. It operates through the North America. 

CEO
Olivier Dominique Loeillot
CEOOlivier Dominique Loeillot
Employees
1,778
Employees1,778
Headquarters
Waltham, Massachusetts
HeadquartersWaltham, Massachusetts
Founded
1981
Founded1981
Employees
1,778
Employees1,778

RGEN Key Statistics

Market cap
9.45B
Market cap9.45B
Price-Earnings ratio
6.61K
Price-Earnings ratio6.61K
Dividend yield
Dividend yield
Average volume
658.24K
Average volume658.24K
High today
$174.87
High today$174.87
Low today
$166.40
Low today$166.40
Open price
$170.75
Open price$170.75
Volume
540.33K
Volume540.33K
52 Week high
$182.52
52 Week high$182.52
52 Week low
$102.97
52 Week low$102.97

Stock Snapshot

As of today, Repligen(RGEN) shares are valued at $167.93. The company's market cap stands at 9.45B, with a P/E ratio of 6613.62.

As of 2026-01-22, Repligen(RGEN) stock has fluctuated between $166.40 and $174.87. The current price stands at $167.93, placing the stock +0.9% above today's low and -4.0% off the high.

The Repligen(RGEN)'s current trading volume is 540.33K, compared to an average daily volume of 658.24K.

In the last year, Repligen(RGEN) shares hit a 52-week high of $182.52 and a 52-week low of $102.97.

In the last year, Repligen(RGEN) shares hit a 52-week high of $182.52 and a 52-week low of $102.97.

Analyst ratings

74%

of 23 ratings
Buy
73.9%
Hold
26.1%
Sell
0%

People also own

Based on the portfolios of people who own RGEN. This list is generated using Robinhood data, and it’s not a recommendation.
All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the Options Disclosure Document.